What is the current stock price of Collegium Pharmaceutical, Inc. (COLL)?

As of the latest market data, Collegium Pharmaceutical, Inc. (COLL) is trading at $33.68. The stock has seen a loss of -0.30% today.

Does Collegium Pharmaceutical, Inc. (COLL) pay a dividend?

Based on current data, Collegium Pharmaceutical, Inc. does not have a confirmed active dividend policy.

What is the market cap of Collegium Pharmaceutical, Inc.?

The current market capitalization of Collegium Pharmaceutical, Inc. (COLL) is approximately unavailable.

COLL

Collegium Pharmaceutical, Inc.·Healthcare

33.68

0.296%(−0.10)

Close Price

34.70

3.029%(+1.02)

Pre-Market

Last Updated: — ET

52W L: $28.7352W H: $50.79

COLL NEWS

globenewswire.com

21h ago

Collegium to Participate in 2026 Jefferies Global Healthcare Conference

STOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference.

globenewswire.com

May 12

Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics

- Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio - - Extends Collegium's Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection Through 2037 - - Collegium Raises 2026 Financial Guidance to Reflect Expected Immediate Accretion from Acquisition - - 2026 Total Product Revenues, Net Expected in the Range of $865 to $895 Million and Adjusted EBITDA in the Range of $475 to $500 Million - STOUGHTON, Mass.

globenewswire.com

May 12

Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics

– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio –

seekingalpha.com

May 7

Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript

zacks.com

May 7

Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com

May 7

Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.76 per share, beating the Zacks Consensus Estimate of $1.42 per share. This compares to earnings of $1.49 per share a year ago.

Company Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

357

IPO Date

2015-05-07

Beta

0.76

Websitewww.collegiumpharma.com↗